{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Liu Y"],"funding":["Fundamental Research Funds for the Central Universities","Jiangsu Excellent Postdoctoral Program","China Postdoctoral Science Foundation","National Natural Science Foundation of China","National Key Research and Development Program of China"],"pagination":["e2300679"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10288280"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(18)"],"pubmed_abstract":["Universal chemotherapy in glioblastoma patients causes chemoresistance and further limits immune cells by creating an immunosuppressive tumor microenvironment that are difficult to solve by single-drug therapeutic approaches. Here, this work designs hybrid drug-loaded nanoliposomes by co-loading the chemotherapeutic drug temozolomide (TMZ) and nitric oxide (NO) prodrug JS-K with sphingosine-1-phosphate molecules (S1P) on the surface. The S1P-S1P receptors axis endows nanoliposomes with rapid targeting and lysosomal escaping capability. Then, fine-tuned TMZ release and NO gas production following JS-K release in glioma microenvironment decrease chemoresistance and increase tumor immunogenicity through inhibiting the cellular autophagy as well as inducing mitochondrial dysfunction. RNA seque"],"journal":["Advanced science (Weinheim, Baden-Wurttemberg, Germany)"],"pubmed_title":["In Situ Nitric Oxide Gas Nanogenerator Reprograms Glioma Immunosuppressive Microenvironment."],"pmcid":["PMC10288280"],"funding_grant_id":["2242022R20043","2022M710687","2022T150117","81971750","2018YFA0704103","2022ZB124"],"pubmed_authors":["Liu Y","Cui L","Ju Y","Wang X","Miao W","Xu H","Gu N","Yang F","Chen T"],"additional_accession":[]},"is_claimable":false,"name":"In Situ Nitric Oxide Gas Nanogenerator Reprograms Glioma Immunosuppressive Microenvironment.","description":"Universal chemotherapy in glioblastoma patients causes chemoresistance and further limits immune cells by creating an immunosuppressive tumor microenvironment that are difficult to solve by single-drug therapeutic approaches. Here, this work designs hybrid drug-loaded nanoliposomes by co-loading the chemotherapeutic drug temozolomide (TMZ) and nitric oxide (NO) prodrug JS-K with sphingosine-1-phosphate molecules (S1P) on the surface. The S1P-S1P receptors axis endows nanoliposomes with rapid targeting and lysosomal escaping capability. Then, fine-tuned TMZ release and NO gas production following JS-K release in glioma microenvironment decrease chemoresistance and increase tumor immunogenicity through inhibiting the cellular autophagy as well as inducing mitochondrial dysfunction. RNA seque","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jun","modification":"2025-04-05T12:14:16.88Z","creation":"2025-02-19T04:29:17.277Z"},"accession":"S-EPMC10288280","cross_references":{"pubmed":["37085663"],"doi":["10.1002/advs.202300679"]}}